A clinical-research network is one of those institutions a free society builds once and then holds in trust. The investigators who learn how to run a trial properly, the teaching hospitals that agree to host one, the patients who agree to be studied — that is fifteen or twenty years of accumulated competence, and it cannot be purchased back once it is sold. Advent International, a Boston-based private-equity firm with $94 billion in assets under management, has just paid about $715 million for a controlling stake in New Zealand Clinical Research, the country’s largest clinical-research operator, in a deal first surfaced in the Australian and New Zealand financial press. There was no auction. There was no competing bid. There was no public list of what comes next. The Sydney office Advent opened in 2024 has now absorbed two healthcare targets. The Tokyo office it opened in January of 2026 has already absorbed its first. The regional playbook is consistent enough to describe: a proprietary approach, a single bidder, the conviction that scale and capital entitle you to name your own price and your own terms. The deals that follow it, by the firm’s own design, will be much harder to see coming.
This is the case for the deal, and it deserves a hearing. Advent brings global capital and operational scale to a New Zealand firm whose regional clinical-research market is being pulled toward Asia and needs platform investment to compete. Waterman Capital, the Auckland-based seller, gets certainty and speed. Advent gets an asset it can compound quietly for fifteen or twenty years — Beau Dixon, the managing director who runs Advent’s Sydney office and who personally walked the deal across the table, says he can double NZCR’s annual revenue in three to five years through organic growth alone. The pitch to investors is conviction: we know what this asset is worth, we don’t need an auction to prove it. That is the strongest honest version of the argument, and it is the version Advent tells.
Here is what it leaves out.
The “no process, no competing bid” feature is sold to the seller as certainty. To the country whose healthcare infrastructure is being quietly assembled, it is the opposite. It means the public, the regulators, the competing providers, the doctors whose patients may end up enrolled in trials owned by an absentee firm — none of them get to see the deal, comment on it, or object to it until the ink is dry. Dixon described the transaction as proprietary, no process, confidential and very, very closely managed. In plain terms: the market was not invited. The country was not invited. The only people in the room were the buyer and the seller.
This is the conservative case, not the liberal one. A liberal voice would object that private equity extracts value from workers and widens inequality; that is not the argument I am making. The argument I am making is older, and it is rooted in the tradition Edmund Burke wrote out two centuries ago: institutions are intergenerational trusts, and a free society has an interest in who owns them. A clinical-research network is not inventory. It is the scaffolding under every drug trial your hospital will run for the next twenty years. When an absentee firm buys it with no public scrutiny, no community input, and no competing bidder, the trust is broken — not by malice, but by the simple fact that the people who depend on it were never asked.
The pattern is the news. Advent’s Sydney team has been open less than two years and has now closed two deals. The Tokyo team has been open five months and has closed one — Japan Wellbeing, a provider of home care for the aged, Advent’s first direct investment in Japan. The pipeline, Dixon said, is up to eighteen months long. The targets are not advertised. The regional healthcare market — fragmented, family-owned, balkanised across hundreds of operators in both Australia and New Zealand — is being quietly assembled into a portfolio held by a Boston firm whose investors will never set foot in the towns where their assets operate. Advent’s prior healthcare experience includes Syneos Health, a pharma-research services provider, and Simtra, a biotech manufacturer. The firm knows what it is buying. It is not interested, Dixon’s framing was careful here, in tuck-ins adjacent to NZCR. It is looking at other areas in health where we feel that we have the requisite conviction based on prior experience.
Read that twice.
What is being assembled, region by region and sector by sector, is a healthcare portfolio held in private hands, with no public list, no auction calendar, and no obligation to disclose what comes next. The model is the private-equity model at full extension: identify a fragmented sector, find the largest player in it, write one cheque, then use the conviction of that first deal to source the next one quietly. The list nobody in New Zealand or Australia gets to see is the list of every healthcare asset in the country Advent is currently talking to.
I know this machine. I spent the better part of a decade trading agricultural futures on a Chicago desk, where I watched the same playbook run on the grain elevators and the seed companies. The futures market does not care whether the farmer’s son stays on the land. The deal team does not care whether the country keeps its clinical-research capacity. They care that the price is right, the conviction is high, and the process is proprietary — because proprietary means nobody else is at the table to mark them up. The financialised layer of the economy eats the productive layer one quiet acquisition at a time. I watched it happen to the corn. I am watching it happen to the medicine.
The conservative tradition I work from has a name for this. Brandeis called it the curse of bigness and made it the spine of an American antitrust argument. Chesterton, across the water, said the trouble was not too much capitalism, but too few capitalists, and meant it. Belloc and the distributists argued that widely distributed productive property — including the productive property of healthcare, of research, of the institutions a free society depends on — is the only durable defense against the slow conversion of a country into a tenant of its own infrastructure. The encyclicals say it in their own way: the earth was given for all, and private property — even private equity — answers to the universal destination of goods. Quadragesimo Anno, in 1931, named the principle that higher bodies should not absorb what smaller ones can do, and that the smaller bodies — the country, the community, the co-op — ought to be the ones who decide what is built and how it is held. The point is not that the Advent deal is illegal. The point is that it is the kind of deal that, multiplied across a sector, hollows out the institutions a free society needs to remain free.
There is a counter-model, and it is older than the private-equity playbook. The cooperative. The member-owned research network. The Rochdale Pioneers who, in 1844, sat down in a Lancashire weavers’ shop and wrote the rules for an institution they owned together, governed by one member one vote, and run for the benefit of the people who used it. The cooperative structure has been shown to scale. Mondragon, founded in 1956 in the Basque country, now employs over seventy thousand people across manufacturing, finance, and healthcare, with an internal pay ratio of roughly five to one. Land O’Lakes, founded in 1921, posted $16.2 billion in sales last year. Organic Valley, headquartered downstate in La Farge, unites sixteen hundred organic family farms and roughly thirty percent of the United States organic milk supply. The rural electric cooperatives electrified the American countryside when the investor-owned utilities would not. The credit-union structure has been shown to lower the cost of capital for the people who save in it. The mutual-insurance structure has been shown to absorb risk without surrendering it to an absentee owner.
A clinical-research network could be owned the same way. The investigators and teaching hospitals that built it could own it together. The trial participants whose data generated its reputation could have a voice in how it is run. The capital to scale it could be raised through patient, distributed ownership rather than a single Boston cheque. The list of what comes next would not be a secret — it would be a plan the members debated and approved. This is not a fantasy. It is a working tradition, with a century and a half of practice behind it, that the financialised layer of the economy has spent the last forty years quietly putting out of business.
I am not arguing that the Advent deal be unwound. The ink is dry, and the new owners will run the firm as they see fit. I am arguing that the next time a country’s healthcare infrastructure is sold quietly, without an auction, without a competing bidder, and without a public list — somebody in that country ought to be awake. The conservative case for an awake citizenry is the same as it was for Burke: institutions are trusts, not commodities; the people who depend on them have an interest in who owns them; and a free society does not survive the slow conversion of its scaffolding into a portfolio. Advent did what private-equity firms are designed to do. The question for the rest of us is whether we will let it be done to us — again, quietly, one proprietary deal at a time — or whether we will build the institutions that let a country keep what it built.
The country’s medicine was sold without an auction. The next one will be, by design, much harder to see coming.